ArticleHaematologica2023

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.

Jesse M Tettero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.